Evotec AG - Product Pipeline Review - 2016

  • ID: 3714979
  • Company Profile
  • 60 pages
  • Global Markets Direct
1 of 4
Evotec AG - Product Pipeline Review - 2016

Summary

‘Evotec AG - Product Pipeline Review - 2016’, provides an overview of the Evotec AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Evotec AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Evotec AG
- The report provides overview of Evotec AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Evotec AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Evotec AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Evotec AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Evotec AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Evotec AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Evotec AG Snapshot

Evotec AG Overview

Key Information

Key Facts

Evotec AG - Research and Development Overview

Key Therapeutic Areas

Evotec AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Evotec AG - Pipeline Products Glance

Evotec AG - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Evotec AG - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Evotec AG - Drug Profiles

EVT-201

Product Description

Mechanism of Action

R&D Progress

EVT-401

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit KDM for Oncology

Product Description

Mechanism of Action

R&D Progress

Drugs for Endometriosis

Product Description

Mechanism of Action

R&D Progress

EVT-070

Product Description

Mechanism of Action

R&D Progress

EVT-601

Product Description

Mechanism of Action

R&D Progress

EVT-701

Product Description

Mechanism of Action

R&D Progress

EVT-801

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Pain

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Type 1 Diabetes and Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Drug for Kidney Diseases

Product Description

Mechanism of Action

R&D Progress

Drugs for Alzheimer's Disease

Product Description

Mechanism of Action

R&D Progress

Drugs for Multiple Sclerosis

Product Description

Mechanism of Action

R&D Progress

Drugs for Tissue Fibrosis

Product Description

Mechanism of Action

R&D Progress

Drugs to Inhibit FGFR3 for Bladder Cancer

Product Description

Mechanism of Action

R&D Progress

Drugs to Target EEM for Type 1 Diabetes and Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Induced Pluripotent Stem Cells for Amyotrophic Lateral Sclerosis

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Chronic Kidney Disease

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Dysferlinopathies

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Glioblastoma Multiforme

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Huntington Disease

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Inflammation

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Multiple Sclerosis

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Neurodegenerative diseases

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Solid Tumor

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize Orexin Receptor 2 for Nacrcolepsy

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PGB for Bacterial Infections

Product Description

Mechanism of Action

R&D Progress

Evotec AG - Pipeline Analysis

Evotec AG - Pipeline Products by Target

Evotec AG - Pipeline Products by Route of Administration

Evotec AG - Pipeline Products by Molecule Type

Evotec AG - Pipeline Products by Mechanism of Action

Evotec AG - Recent Pipeline Updates

Evotec AG - Dormant Projects

Evotec AG - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

EVT-301

sembragiline

ocaperidone

REN-1654

REN-213

REN-850

Evotec AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Evotec AG, Key Information

Evotec AG, Key Facts

Evotec AG - Pipeline by Indication, 2016

Evotec AG - Pipeline by Stage of Development, 2016

Evotec AG - Monotherapy Products in Pipeline, 2016

Evotec AG - Partnered Products in Pipeline, 2016

Evotec AG - Partnered Products/ Combination Treatment Modalities, 2016

Evotec AG - Out-Licensed Products in Pipeline, 2016

Evotec AG - Out-Licensed Products/ Combination Treatment Modalities, 2016

Evotec AG - Phase II, 2016

Evotec AG - Phase I, 2016

Evotec AG - Preclinical, 2016

Evotec AG - Discovery, 2016

Evotec AG - Pipeline by Target, 2016

Evotec AG - Pipeline by Route of Administration, 2016

Evotec AG - Pipeline by Molecule Type, 2016

Evotec AG - Pipeline Products by Mechanism of Action, 2016

Evotec AG - Recent Pipeline Updates, 2016

Evotec AG - Dormant Developmental Projects,2016

Evotec AG - Discontinued Pipeline Products, 2016

Evotec AG, Subsidiaries

List of Figures

Evotec AG - Pipeline by Top 10 Indication, 2016

Evotec AG - Pipeline by Stage of Development, 2016

Evotec AG - Monotherapy Products in Pipeline, 2016

Evotec AG - Partnered Products in Pipeline, 2016

Evotec AG - Out-Licensed Products in Pipeline, 2016

Evotec AG - Pipeline by Target, 2016

Evotec AG - Pipeline by Molecule Type, 2016

Evotec AG - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll